Medicare Enrolled
Dr. Michael Zlupko
Pulmonary Disease · Altoona, PA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Zlupko from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Zlupko?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Zlupko
Dr. Michael Zlupko is a pulmonary disease specialist in Altoona, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Zlupko performed 2,484 Medicare services across 1,306 unique beneficiaries.
Between the years covered by Open Payments, Dr. Zlupko received a total of $377,236 from 54 pharmaceutical and/or device companies across 1173 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Zlupko is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 6% volume in PA
$377,236 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,484
Medicare services
Top 6% in PA for pulmonary disease
1,306
Unique beneficiaries
$64
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~131 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
820 | $62 | $101 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
469 | $90 | $175 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
282 | $19 | $85 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
209 | $93 | $123 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
149 | $42 | $150 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
113 | $102 | $175 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
87 | $28 | $125 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
85 | $32 | $180 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
66 | $39 | $50 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
46 | $48 | $103 |
| New patient office visit, complex (60-74 min) | 41 | $159 | $250 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
30 | $24 | $25 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
24 | $76 | $100 |
| Exhaled air and carbon dioxide test A test that measures exhaled air and carbon dioxide levels to evaluate lung function. |
22 | $34 | $75 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
21 | $156 | $444 |
| Chest X-ray, 2 views An X-ray imaging test of the chest that captures two different angles to visualize the lungs, heart, and chest wall. |
20 | $25 | $75 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$377,236
Total received (2018-2024)
Avg $53,891/year across 7 years
Top 1% in PA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
54
Companies
1,173
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$278,231 (73.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$89,851 (23.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,154 (2.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$49,920
2023
$81,557
2022
$56,129
2021
$62,440
2020
$35,860
2019
$67,593
2018
$23,736
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$18,829
Boehringer Ingelheim Pharmaceuticals, Inc.
$11,470
Insmed, Inc.
$10,110
Grifols USA, LLC
$6,776
GENZYME CORPORATION
$1,393
AstraZeneca Pharmaceuticals LP
$400
Actelion Pharmaceuticals US, Inc.
$132
Regeneron Healthcare Solutions, Inc.
$124
Inspire Medical Systems, Inc.
$121
Mallinckrodt Hospital Products Inc.
$118
Avadel CNS Pharmaceuticals, LLC
$77
Vifor Pharma, Inc.
$64
Amgen Inc.
$50
Genentech USA, Inc.
$49
Mylan Specialty L.P.
$40
Electromed, Inc.
$33
Pulmonx Corporation
$31
HARMONY BIOSCIENCES LLC
$25
United Therapeutics Corporation
$23
Philips North America LLC
$22
ABBVIE INC.
$19
Paratek Pharmaceuticals, Inc.
$15
Top 3 companies account for 80.9% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$168,114
Boehringer Ingelheim Pharmaceuticals, Inc.
$96,807
Grifols USA, LLC
$55,776
Insmed, Inc.
$44,601
AstraZeneca Pharmaceuticals LP
$2,218
GENZYME CORPORATION
$1,753
United Therapeutics Corporation
$1,192
Actelion Pharmaceuticals US, Inc.
$830
Grifols Shared Services North America, Inc.
$540
Gilead Sciences, Inc.
$442
PFIZER INC.
$441
Regeneron Healthcare Solutions, Inc.
$404
Mylan Specialty L.P.
$347
Genentech USA, Inc.
$342
Ethicon Inc.
$330
JAZZ PHARMACEUTICALS INC.
$288
Electromed, Inc.
$239
Mallinckrodt Hospital Products Inc.
$198
Bayer HealthCare Pharmaceuticals Inc.
$160
Novartis Pharmaceuticals Corporation
$155
Takeda Pharmaceuticals U.S.A., Inc.
$142
Inspire Medical Systems, Inc.
$139
SANOFI-AVENTIS U.S. LLC
$138
Jazz Pharmaceuticals Inc.
$102
Veran Medical Technologies, Inc.
$102
Resmed Corp
$98
Harmony Biosciences LLC
$92
AbbVie Inc.
$86
ZOLL Respicardia, Inc.
$81
Paratek Pharmaceuticals, Inc.
$78
Avadel CNS Pharmaceuticals, LLC
$77
Amgen Inc.
$69
Sunovion Pharmaceuticals Inc.
$68
Vifor Pharma, Inc.
$64
Advanced Respiratory, Inc
$64
Baxter Healthcare
$62
Circassia Pharmaceuticals Inc
$57
Merck Sharp & Dohme LLC
$53
Teva Pharmaceuticals USA, Inc.
$51
Philips Electronics North America Corporation
$48
Pulmonx Corporation
$46
Merck Sharp & Dohme Corporation
$45
ADVANCED RESPIRATORY, INC
$41
Allergan, Inc.
$40
Allergan Inc.
$39
Shire North American Group Inc
$31
HARMONY BIOSCIENCES LLC
$25
Vapotherm Inc
$23
Philips North America LLC
$22
ABBVIE INC.
$19
Melinta Therapeutics, Inc.
$17
IDORSIA PHARMACEUTICALS US INC
$17
Optinose US, Inc.
$15
E.R. Squibb & Sons, L.L.C.
$11
Top 3 companies account for 85.0% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · ACTHAR · AIRCURVE · AIRSUPRA · ANORO · ANORO ELLIPTA · APNEALINK · AREXVY · ASMANEX · AVYCAZ · Adempas · AirDuo Digihaler · AirSense · Arikayce · Astral · BELSOMRA · BEVESPI AEROSPHERE · BREO · BREZTRI · CHANTIX · CHARTIS CATHETER · CINQAIR · DALVANCE · DUAKLIR PRESSAIR · DUPIXENT · ELIQUIS · Esbriet · FARXIGA · FASENRA · FLUARIX · FLULAVAL · GLASSIA · Hillrom - Life 2000 Ventilation System · Hillrom - Monarch Airway Clearance System · Hillrom - Vest System Model 105 Home Care · INSPIRE · LONHALA MAGNAIR · LUMRYZ · Letairis · Life 2000 Ventilation System · Monarch Platform · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · PREVNAR 13 · Perforomist · Prolastin-C · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · QUVIVIQ · SHINGRIX · SMARTVEST · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Spin · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The MetaNeb System · The Vest System Model 105 Home Care · UPTRAVI · Utibron · Vabomere · WAKIX · Wakix · XOLAIR · XYWAV · Xembify · Xhance · Xolair · Xyrem · YUPELRI · Yupelri · Zemaira · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (74%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for pulmonary disease in PA.
Geographic Context
Pulmonary diseases within 10 mi
6
Per 100K population
4.9
County median income
$60,594
Nearest hospital
UPMC ALTOONA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Zlupko is a clinical cardiology specialist, with above-average Medicare volume (top 6% in PA), with speaking/promotional industry engagement in the top 1% of PA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Zlupko experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Zlupko performed 820 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Zlupko receive payments from pharmaceutical companies?
Yes. Dr. Zlupko received a total of $377,236 from 54 companies across 1,173 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Zlupko's costs compare to other pulmonary diseases in Altoona?
Dr. Zlupko's average Medicare payment per service is $64. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Zlupko) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Altoona
Browse pulmonary diseases in Altoona ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in PA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in PA
Which PA pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
Grifols USA, LLC Payments to Doctors
See all physicians who received payments from Grifols USA, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology